Michael Morelli's Epithalon + Pinealon sleep & brain peptide stack
Epithalon + Pinealon are two of the most overlooked peptides for sleep and brain health. They have 40+ years of Russian research behind them. I've been using them for a few weeks, and the effects on my sleep have been incredible.
The standard Khavinson playbook: two pineal-derived peptides, an appeal to '40+ years of Russian research' that isn't replicated outside one St Petersburg lab, no doses, and 'incredible' sleep results inside the textbook placebo window. Epithalon at least has a plausible melatonin-axis mechanism; Pinealon is along for the ride with even thinner data. Calling these 'overlooked' is generous — they're available everywhere with the marketing already written.
| Goal | Score | Grade | Weight | Why |
|---|---|---|---|---|
| Longevity | — | Not targeted | — | Not claimed in this tweet. Epithalon is canonically marketed for longevity, but Morelli explicitly frames the stack as sleep + brain. |
| Cognition | 62 | D- | 40% | Pinealon's 'brain health' claim rests on Khavinson-group neuroprotection studies that haven't been independently replicated; the mechanism is plausible but the human evidence is essentially absent. |
| Sleep & recovery | 65 | D | 60% | Epithalon has a melatonin/pineal mechanism that's at least directionally relevant to circadian-driven sleep; the claim is not crazy, but it's undosed and skips every first-line sleep intervention. |
| Energy & metabolism | — | Not targeted | — | Neither peptide has a metabolic mechanism. |
| Body recomposition | — | Not targeted | — | No anabolic agent or training stimulus in the stack. |
Ingredients (2)
Epithalon
Epithalon on peptidelist.org ↗
- Dose
- unspecified
- Mechanism
- Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a pineal extract; claimed to upregulate telomerase, restore age-related decline in melatonin secretion, and normalize circadian rhythms. Mechanism is plausible for the melatonin/sleep axis but the supporting human trials are essentially one Russian research group.
- Take
- Morelli discloses zero dosing. The published Khavinson protocols are typically 5–10mg/day subcutaneously for 10–20 days, cycled. Without a dose, the post is unfalsifiable — readers can't compare against the research, can't recognize sub- or supratherapeutic use, and can't reproduce the claimed sleep effect. Saying 'I've been using them' is the same epistemic gap a vendor blend has.
Pinealon
- Dose
- unspecified
- Mechanism
- Synthetic tripeptide (Glu-Asp-Arg) developed by the same Khavinson / St Petersburg Institute of Bioregulation and Gerontology lineage; proposed to cross the blood-brain barrier and exert neuroprotective effects via gene expression modulation. Mechanism in humans is not characterized.
- Take
- Pinealon has even thinner published support than Epithalon — a handful of in vitro and animal papers from the Khavinson group on neuroprotection and oxidative stress, and essentially no controlled human data. Common protocol guidance from peptide vendors is 5–10mg/day for short cycles, but that's vendor lore, not a clinical reference range. Stacking it next to Epithalon also makes any n=1 attribution to either peptide impossible.
Risks & interactions
- Zero dose disclosure on either peptidehigh
Morelli names two compounds and a personal benefit but no dose, no timing, no cycle length, no route. Readers who copy the stack will end up at whatever a vendor product page recommends, which has no clinical anchor. For an influencer post that's going to drive purchase decisions, the absence of a single number is the load-bearing problem with the stack.
- '40+ years of Russian research' is the canonical citation-without-citing movehigh
The Epithalon and Pinealon evidence base traces almost entirely to Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology. The volume of work is real; the independent replication outside that lab is essentially nonexistent. 'Decades of research' is technically true and epistemically misleading — modern Western RCT-grade evidence does not support the headline claims (telomerase upregulation, restored melatonin secretion, neuroprotection).
- Three-week 'incredible' sleep effect is the textbook placebo signaturemedium
Sleep is one of the most placebo-responsive endpoints in self-experimentation, especially when the metric is subjective ('how rested do I feel') and the user is consciously expecting improvement. A few-weeks anecdote with no objective measure (sleep tracker baseline, HRV, sleep diary) is exactly the case where confirmation bias dominates.
- Research-peptide sourcing with no FDA approval or pharmacopeial standardmedium
Neither Epithalon nor Pinealon is FDA-approved for any indication. Both are sold as 'research chemicals,' meaning purity, sterility, and labeling vary by vendor. The harm risk for short cycles at typical doses is low, but the user has no way to verify what's in the vial.
- First-line sleep workup skippedlow
If the underlying problem is sleep, the high-evidence interventions are sleep apnea screening, fixed wake times, light exposure timing, caffeine cutoff, and CBT-i for chronic insomnia. None of these are mentioned. Reaching for an obscure peptide before ruling out apnea is the same anti-pattern as reaching for a nootropic before fixing sleep.
Pinealon is the weaker of the two by every available standard — thinner published evidence, no characterized human mechanism, no clinical dose range. Stacking it next to Epithalon also makes the n=1 attribution impossible: Morelli can't tell which peptide (if either) is doing anything. Drop Pinealon, run Epithalon at a published Khavinson-protocol dose with an objective sleep tracker for a baseline-vs-on comparison, and the experiment actually becomes interpretable.
Estimated cost
Research-peptide vendor pricing for 2 peptides run at typical 5–10mg/day cycles. Epithalon ~$30–80/mo, Pinealon ~$30–80/mo depending on vendor and bacteriostatic water / syringe costs. Sourcing risk applies — purity is not guaranteed.